Pharvaris Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Erträge von Pharvaris sind jährlich um durchschnittlich -43.8% zurückgegangen, während in der Branche Pharmaceuticals die Erträge jährlich um rückgegangen sind und sich dabei auf 0.4% belaufen.

Wichtige Informationen

-41.6%

Wachstumsrate der Gewinne

8.1%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	6.0%
Wachstumsrate der Einnahmen	n/a
Eigenkapitalrendite	-34.3%
Netto-Marge	n/a
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Keine Aktualisierungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie Pharvaris Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:PHVS Einnahmen, Ausgaben und Erträge (EUR Millions)
Datum	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	-114	37	79
31 Mar 24	-106	34	70
31 Dec 23	-101	31	66
30 Sep 23	-107	30	63
30 Jun 23	-92	31	59
31 Mar 23	-83	31	58
31 Dec 22	-76	29	57
30 Sep 22	-49	27	52
30 Jun 22	-50	23	47
31 Mar 22	-53	20	41
31 Dec 21	-43	18	36
30 Sep 21	-41	15	33
30 Jun 21	-38	12	29
31 Mar 21	-29	8	25
31 Dec 20	-26	5	20
30 Sep 20	-19	4	14
31 Dec 19	-8	2	6

Qualität der Erträge: PHVS ist derzeit unrentabel.

Wachsende Gewinnspanne: PHVS ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: PHVS ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 43.8% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von PHVS verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: PHVS ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (19.9%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: PHVS hat eine negative Eigenkapitalrendite (-29.59%), da es derzeit unrentabel ist.

Pharvaris Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Pharvaris Expands Development Program for Deucrictibant

Co-Founder notifies of intention to sell stock

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Early Development Officer notifies of intention to sell stock

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Independent Vice Chairman notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris: Digging Deep For Sufficient Market Size

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023

New major risk - Shareholder dilution

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Co-Founder notifies of intention to sell stock

Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer

New major risk - Revenue and earnings growth

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Announces Board Changes

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris N.V., Annual General Meeting, Jun 23, 2023

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Less than half of directors are independent

Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V., Annual General Meeting, Jun 29, 2022

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris N.V. Appoints Joan Schmidt as Chief Legal Officer

Less than half of directors are independent

High number of new and inexperienced directors

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris reports Q1 results

Independent Non-Executive Director has left the company

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE

Pharvaris B.V. has completed an IPO in the amount of $165.41 million.

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren